Literature DB >> 9039238

British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.

I D Johnston1, R J Prescott, J C Chalmers, R M Rudd.   

Abstract

BACKGROUND: Mortality due to cryptogenic fibrosing alveolitis (CFA) is increasing, particularly in the elderly. Optimum management remains uncertain and previous studies of the disease have largely been from specialist centres. A national study was carried out of the presentation and initial management of CFA in the UK.
METHODS: All respiratory physicians in England, Scotland and Wales were invited to enter patients with newly diagnosed CFA over a two year period. CFA was diagnosed on histological grounds or according to clinical criteria which included the absence of a defined connective tissue disorder or pneumoconiosis. Participating physicians (n = 150) completed a questionnaire at patient entry and at all subsequent follow up visits and death.
RESULTS: A total of 588 patients (373 men, 63%) were studied of whom 441 (75%) were referrals from primary care. Their mean (SD) age was 67.4 (10.0) years and median duration of symptoms at presentation was 9.0 months. Clubbing was more common in men (203/373; 54%) than in women (86/ 215; 40%); 209 patients (36%) were graded as severely breathless at presentation. A history of dust exposure (organic or inorganic) was present in 274 patients (47%) of whom 87 had had some exposure to asbestos. Subjects exposed to dust were more likely to have smoked and had slightly higher mean lung volumes, but were otherwise indistinguishable from those not exposed in terms of clinical presentation, management, and outcome. Transbronchial biopsy specimens were taken in 164 patients (28%) and open lung biopsy specimens in 73 (12%), but 60% had no histological diagnostic procedure. Biopsy procedures were more likely to be performed in younger patients, those with better lung function, and those with a history of asbestos exposure. At presentation a decision not to initiate specific treatment was made in 284 cases (48%). The decision to initiate treatment was made predominantly on symptomatic grounds. Two years after the close of entry to the study 266 patients (45%) had died.
CONCLUSIONS: CFA is predominantly a disease of elderly patients and has a poor prognosis. Physicians generally considered CFA to be a clinical diagnosis and did not initiate treatment in up to half of patients at presentation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039238      PMCID: PMC1758413          DOI: 10.1136/thx.52.1.38

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  Cryptogenic fibrosing alveolitis. A study of an indigenous African population.

Authors:  C Smith; C Feldman; H Levy; J M Kallenbach; S Zwi
Journal:  Respiration       Date:  1990       Impact factor: 3.580

2.  The prognosis of cryptogenic fibrosing alveolitis.

Authors:  B H Stack; Y F Choo-Kang; B E Heard
Journal:  Thorax       Date:  1972-09       Impact factor: 9.139

3.  Mortality rates from cryptogenic fibrosing alveolitis in seven countries.

Authors:  R Hubbard; I Johnston; D B Coultas; J Britton
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

4.  Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis.

Authors:  R Hubbard; S Lewis; K Richards; I Johnston; J Britton
Journal:  Lancet       Date:  1996-02-03       Impact factor: 79.321

Review 5.  Diffuse lung disease: an approach to management.

Authors:  R M du Bois
Journal:  BMJ       Date:  1994-07-16

6.  Prognosis of cryptogenic fibrosing alveolitis.

Authors:  P Tukiainen; E Taskinen; P Holsti; O Korhola; M Valle
Journal:  Thorax       Date:  1983-05       Impact factor: 9.139

7.  Natural history and treated course of usual and desquamative interstitial pneumonia.

Authors:  C B Carrington; E A Gaensler; R E Coutu; M X FitzGerald; R G Gupta
Journal:  N Engl J Med       Date:  1978-04-13       Impact factor: 91.245

8.  The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom.

Authors:  I D Johnston; S A Gomm; S Kalra; A A Woodcock; C C Evans; C R Hind
Journal:  Eur Respir J       Date:  1993-06       Impact factor: 16.671

9.  Diffuse interstitial fibrosis in nonasbestos pneumoconiosis--a pathological study.

Authors:  K Honma; K Chiyotani
Journal:  Respiration       Date:  1993       Impact factor: 3.580

10.  Idiopathic pulmonary fibrosis in asbestos-exposed workers.

Authors:  E A Gaensler; P J Jederlinic; A Churg
Journal:  Am Rev Respir Dis       Date:  1991-09
  10 in total
  33 in total

Review 1.  Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis.

Authors:  A Wells
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  Interferon gamma-1b therapy for cryptogenic fibrosing alveolitis.

Authors:  J Britton
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 3.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

Review 4.  Review of cryptogenic fibrosing alveolitis, including current treatment guidelines.

Authors:  S C Bourke; H Clague
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 5.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

6.  Gender influences the response to experimental silica-induced lung fibrosis in mice.

Authors:  David M Brass; Sean P McGee; Mary K Dunkel; Sarah M Reilly; Jacob M Tobolewski; Tara Sabo-Attwood; Cheryl L Fattman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-20       Impact factor: 5.464

7.  Effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis.

Authors:  Jeffrey C Munson; Maryl Kreider; Zhen Chen; Jason D Christie; Stephen E Kimmel
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

8.  Adult familial cryptogenic fibrosing alveolitis in the United Kingdom.

Authors:  R P Marshall; A Puddicombe; W O Cookson; G J Laurent
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

Review 9.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

10.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.

Authors:  D W Mapel; W C Hunt; R Utton; K B Baumgartner; J M Samet; D B Coultas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.